|
Acute lymphocytic leukemia
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Here, we investigated the mutual expression of the Survivin/EPR-1 genes in 12 normal peripheral blood (PB) specimens, seven normal bone marrow (BM) specimens, five lymph node (LN) specimens, and seven leukemic cell lines, and 27 patients with malignant lymphoma (ML), four with acute lymphocytic leukemia (ALL), three with acute myelocytic leukemia (AML), and four with chronic myelocytic leukemia in blastic crisis (CML-BC).
|
11086180 |
2000 |
|
Acute lymphocytic leukemia
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Relapse of drug-resistant acute lymphoblastic leukemia (ALL) has been associated with increased expression of survivin/BIRC5, an inhibitor of apoptosis protein, suggesting a survival advantage for ALL cells.
|
21715311 |
2011 |
|
Acute lymphocytic leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
To validate these findings and document whether Wnt inhibition may sensitize cells to chemotherapy, we analysed the expression of activated β-catenin (and its downstream target BIRC5) using multiparameter phosphoflow cytometry and tested the efficacy of a recently developed Wnt inhibitor, iCRT14, in ALL cell lines and patient samples.
|
24995804 |
2014 |
|
Acute Megakaryocytic Leukemias
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis.
|
16166298 |
2005 |
|
Acute monocytic leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Quantitative expression analyses of BIRC5 mRNA (n = 306) and survivin transcript splice variants (n = 90) were performed on diagnostic bone marrow samples from children with de novo AML treated on the clinical trials CCG-2961 and AAML03P1, then correlated with disease characteristics and clinical outcome.
|
24127439 |
2014 |
|
Acute pancreatitis
|
0.200 |
Biomarker
|
disease |
RGD |
[Expression of survivin gene in a rat model of acute pancreatitis].
|
19726343 |
2009 |
|
Acute Promyelocytic Leukemia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Survivin isoform expression in arsenic trioxide-treated acute promyelocytic leukemia cell line and patients: The odd expression pattern of survivin-2α.
|
27770503 |
2017 |
|
Adenocarcinoma
|
0.360 |
Biomarker
|
group |
CTD_human |
PIAS3, SHP2 and SOCS3 Expression patterns in Cervical Cancers: Relevance with activation and resveratrol-caused inactivation of STAT3 signaling.
|
26432044 |
2015 |
|
Adenocarcinoma
|
0.360 |
AlteredExpression
|
group |
LHGDN |
Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer.
|
16826583 |
2006 |
|
Adenocarcinoma
|
0.360 |
AlteredExpression
|
group |
LHGDN |
Survivin in esophageal cancer: An accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma.
|
16671090 |
2006 |
|
Adenocarcinoma
|
0.360 |
Biomarker
|
group |
BEFREE |
Then, using BIRC5 as a candidate, the prognostic value in LAD and TN adenocarcinomas was verified by the Kaplan-Meier plotter and The Cancer Genome Atlas (TCGA) database, respectively.
|
31093306 |
2019 |
|
Adenocarcinoma
|
0.360 |
AlteredExpression
|
group |
BEFREE |
The positive rate of EPR-1 expression in the primary gastric adenocarcinomas, invasion tumor node and lymph node metastasis was 65.83%, 55.29% and 68%, respectively.
|
15112339 |
2004 |
|
Adenocarcinoma
|
0.360 |
AlteredExpression
|
group |
BEFREE |
Specifically, we found that BIRC5, which codes for survivin, is upregulated in both adenocarcinoma and squamous cell carcinoma tissues and that high expression of BIRC5 is associated with poor survival in adenocarcinoma, but not squamous cell carcinoma.
|
29416000 |
2018 |
|
Adenocarcinoma
|
0.360 |
AlteredExpression
|
group |
LHGDN |
Comparative study of various biological parameters, including expression of survivin, between primary and metastatic human colonic adenocarcinomas.
|
12168867 |
2002 |
|
Adenocarcinoma of lung (disorder)
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our results suggest that the miR-195/BIRC5 axis is a potential target for treatment of lung adenocarcinoma specifically, and NSCLC in general.
|
29416000 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.030 |
Biomarker
|
disease |
BEFREE |
Prognostic Value of BIRC5 in Lung Adenocarcinoma Lacking EGFR, KRAS, and ALK Mutations by Integrated Bioinformatics Analysis.
|
31093306 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
To find novel prognostic factors, we used the expression profile of a poor prognostic factor of lung cancer, survivin (BIRC5), as a template to search for and compare transcriptome expression profiles in a lung adenocarcinoma microarray dataset.
|
17254769 |
2007 |
|
Adenocarcinoma, Basal Cell
|
0.300 |
Biomarker
|
disease |
CTD_human |
PIAS3, SHP2 and SOCS3 Expression patterns in Cervical Cancers: Relevance with activation and resveratrol-caused inactivation of STAT3 signaling.
|
26432044 |
2015 |
|
Adenocarcinoma, Oxyphilic
|
0.300 |
Biomarker
|
disease |
CTD_human |
PIAS3, SHP2 and SOCS3 Expression patterns in Cervical Cancers: Relevance with activation and resveratrol-caused inactivation of STAT3 signaling.
|
26432044 |
2015 |
|
Adenocarcinoma, Tubular
|
0.300 |
Biomarker
|
disease |
CTD_human |
PIAS3, SHP2 and SOCS3 Expression patterns in Cervical Cancers: Relevance with activation and resveratrol-caused inactivation of STAT3 signaling.
|
26432044 |
2015 |
|
Adenoma
|
0.010 |
Biomarker
|
group |
LHGDN |
Histopathological study of intraductal papillary mucinous tumor of the pancreas: special reference to the roles of Survivin and p53 in tumorigenesis of IPMT.
|
12794243 |
2002 |
|
Adenomatous Polyposis Coli
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Neither genistein nor daidzein affected APC (adenomatous polyposis coli) or survivin (BIRC5) expression when cells were treated with concentrations of 10 or 50 μM.
|
24390805 |
2014 |
|
Adult Acute Lymphocytic Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Relapse of drug-resistant acute lymphoblastic leukemia (ALL) has been associated with increased expression of survivin/BIRC5, an inhibitor of apoptosis protein, suggesting a survival advantage for ALL cells.
|
21715311 |
2011 |
|
Adult Burkitt Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In parallel with this observation, BIRC5/Survivin expression was higher in Burkitt's lymphoma and diffuse large B-cell lymphoma than in non-tumoural germinal centre cells.
|
15880597 |
2005 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In parallel with this observation, BIRC5/Survivin expression was higher in Burkitt's lymphoma and diffuse large B-cell lymphoma than in non-tumoural germinal centre cells.
|
15880597 |
2005 |